arrow
P

Peter S. Nelson

Fred Hutchinson Cancer Center
H指数:113
被引数:6.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

tRNA dosage regulates lineage dependency and resistance in prostate cancer

tRNA剂量调控前列腺癌细胞谱系依赖性和耐药性

Nature
IF48.5
2026-10-070
OA
Evolution and heterogeneity of lethal metastatic bladder cancer subtypes

致死性转移性膀胱癌亚型的演化和异质性

Nature
IF48.5
2026-09-160
OAAI
A genome-wide CRISPR screen in human prostate cancer cells reveals drivers of macrophage-mediated cell killing and positions AR as a tumor-intrinsic immunomodulator

全基因组CRISPR筛选在人前列腺癌细胞中揭示了巨噬细胞介导的细胞杀伤的驱动因子,并将AR定位为肿瘤内源性免疫调节因子

2026-07-280
PRE
Multiomic assessments of LNCaP and derived cell strains reveal determinants of prostate cancer pathobiology

多组学评估揭示了LNCaP及其衍生细胞系在前列腺癌病理生物学中的决定因素

2025-11-170
OA
Genome-scale CRISPR screens identify PTGES3 as a direct modulator of androgen receptor function in advanced prostate cancer

基因组规模CRISPR筛选确定PTGES3为晚期前列腺癌雄激素受体功能的直接调节因子

2025-11-050
OAAI
Elucidating molecularly stratified single agent, and combination, therapeutic strategies targeting MCL1 for lethal prostate cancer

阐明靶向MCL1的分子分层单药及联合治疗策略,以治疗致命性前列腺癌

2025-10-080
OAAI
Epigenetic profiling identifies markers of endocrine resistance and therapeutic options for metastatic castration-resistant prostate cancer

表观遗传谱分析鉴定了内分泌抵抗的标志物及转移性去势抵抗性前列腺癌的治疗选择

2025-07-020
OAAI
Results from a Phase 2 Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in the Treatment of Patients with Metastatic Castration-resistant Prostate Cancer with DNA Homologous Recombination Repair Deficiency

多西他赛和卡铂诱导治疗伴DNA同源重组修复缺陷的转移性去势抵抗性前列腺癌患者的2期研究结果

2025-05-230
PRE
Novel Skp1 inhibitor has potent preclinical efficacy against castration-resistant prostate cancer

新型Skp1抑制剂对去势抵抗性前列腺癌具有显著的体外疗效。

2025-04-190
PRE
Reprogramming of Androgen Receptor Activity in Castration-resistant Prostate Cancer is Shaped by Truncated Variants
2025-04-110
OAAI
Racial variation in the advanced prostate cancer genome

晚期前列腺癌基因组中的种族差异

2025-03-310
OA
Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes
2025-02-070
PRE
Increased nuclear factor I-mediated chromatin access drives transition to androgen receptor splice variant dependence in prostate cancer

核因子I介导的染色质可及性增加驱动前列腺癌向雄激素受体剪接变异体依赖性转变

2025-01-011
OA
PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received 177Lu-PSMA-617: Importance of 18F-FDG-Avid Discordant Findings

基于PET的TheraP资格及VISION试验合格患者中接受177Lu-PSMA-617治疗的转移性去势抵抗性前列腺癌患者的结局:18F-FDG显像不一致结果的重要性

2024-11-141
PRE